Associated Papers
STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment.
Samra S et al.
The Journal of Allergy and Clinical Immunology. Global, 2025
CoDIAC: A comprehensive approach for interaction analysis reveals novel insights into SH2 domain function and regulation.
Kandoor A et al.
Biorxiv : the Preprint Server for Biology, 2025
39091881 (PubMed )
Supplement: media-5.xlsx › B.Mutation_classification
JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders.
Djidjik R et al.
Frontiers in Immunology, 2025
41438753 (PubMed )
Supplement: Table1.pdf
Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease.
Sharma M et al.
The Journal of Experimental Medicine, 2023
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Bruscaggin A et al.
Blood Advances, 2021
34500472 (PubMed )
Supplement: advancesADV2021004528-suppl2.xlsx › Table_S7
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y et al.
Ebiomedicine, 2020
32304999 (PubMed )
Supplement: mmc1.xlsx › 4.mutations
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E et al.
Blood, 2018
Select a paper to view details